Plaintiff

Celgene Corp.

9 cases as plaintiff.

Cases
9
Active
0
9 closed
Filed
2017–2025
Top venue
D. New Jersey
7 cases
Also appears as a defendant in 11 cases → View as defendant

Watchlist

Get alerted when Celgene Corp. sues again.

Email-only, free, anonymous. We'll notify you when Celgene Corp. files another patent-infringement lawsuit. One-click unsubscribe from any alert.

Filing activity

2017: 2 cases2'17'182019: 2 cases'19'20'212022: 1 case'22'23'242025: 1 case'25
Cases filed per year with Celgene Corp. as plaintiff.

Celgene Corp. v. Cipla Ltd.

consent judgment; closed
Docket:
2:25-cv-01147
Filed:
2025-02-10
Terminated:
2025-09-17
Patents:8828427999346710555939
π Celgene Corp.Δ Cipla Ltd.

Hatch-Waxman ANDA litigation concerning Cipla ANDA No. 219718 (1/2/3/4 mg). Consent judgment entered Sept. 11, 2025; case closed Sept. 17, 2025. Patents-in-suit: 8,828,427; 9,993,467; 10,555,939. Injunction until expiration; no damages.

Celgene Corp. v. MSN Laboratories Private Limited et al.

consent judgment
Docket:
2:22-cv-01993
Filed:
2022-04-06
Terminated:
2022-06-15
Patents:8828427819826286739398735428999346710555939
π Celgene Corp.Δ MSN Laboratories Private LimitedΔ MSN Pharmaceuticals Inc.

Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.

Celgene Corp. v. Dr. Reddy's Laboratories, Ltd. et al.

consent judgment
Docket:
2:19-cv-15343; 2:21-cv-02111
Filed:
2019-07-12
Terminated:
2022-01-28
Patents:86739398198262873542888284279993467
π Celgene Corp.Δ Dr. Reddy's Laboratories, Ltd.Δ Dr. Reddy's Laboratories, Inc.

Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.

Celgene Corp. v. Hetero Labs Ltd. et al.

terminated
Docket:
2:17-cv-03387
Filed:
2017-05-11
Terminated:
2021-08-19
Patents:8828427
π Celgene Corp.Δ Hetero Labs Ltd.Δ Hetero Labs Ltd. Unit-VΔ Hetero Drugs Ltd.Δ Hetero USA, Inc.Δ Aurobindo Pharma Ltd.Δ Aurobindo Pharma USA, Inc.Δ Aurolife Pharma LLCΔ Eugia Pharma Specialties Ltd.Δ Apotex Inc.Δ Apotex Corp.Δ Mylan Pharmaceuticals, Inc.Δ Mylan Inc.Δ Mylan N.V.Δ Breckenridge Pharmaceutical, Inc.

Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.

Celgene Corp. v. Sandoz Inc.

consent judgment
Docket:
2:25-cv-16878
Terminated:
2025-11-17
Patents:8828427999346710555939
π Celgene Corp.Δ Sandoz Inc.

Hatch-Waxman ANDA litigation concerning Sandoz ANDA No. 220741. Consent judgment Nov. 17, 2025: permanent injunction barring Sandoz's ANDA product until expiration of patents-in-suit; § 271(e)(1) and Paragraph IV rights expressly preserved.

Celgene Corp. v. Mylan

dismissed
Docket:
2:19-cv-05802
Patents:8828427
π Celgene Corp.Δ Mylan

Identified in the Cigna complaint as Celgene Corp. v. Mylan; opinion at 2020 WL 12570814 (D.N.J. Sept. 25, 2020) granted Mylan's motion to dismiss for improper venue.